United Therapeutics scores another FDA approval
United Therapeutics Corp. can add another regulatory thumbs-up to its growing collection.
The Silver Spring biotech has earned Food and Drug Administration approval for another use of Orenitram, a pulmonary arterial hypertension drugs first approved in 2013 to improve patients’ ability to exercise. The agency’s new stamp means the drug’s label can now reflect that it delays the d isease’s progression when used with another type of PAH therapy, United Therapeutics (NASDAQ: UTHR) said Monday.
In…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Health Management | Hypertension | Sports Medicine